PPLPHARMA — Piramal Pharma (Mumbai) Share News
0.000.00%
Last trade - 00:00- IN₹262.00bn
- IN₹304.53bn
- IN₹88.69bn
Brief: Piramal Pharma (Mumbai) Says Tax Authority Confirms Demand Of 40.6 Million Rupees And Imposes Equivalent Penalty
India's Piramal Pharma falls after US FDA observations at UK facility
Brief: Piramal Pharma Says US FDA Issues Form-483 With 7 Observations To Morpeth UK Facility
Brief: Piramal Pharma Approves Exercise Of Call Option For Acquisition Of Additional 41% Equity In Yapan Bio
Brief: Piramal Pharma Resumes Operations At Ahmedabad, Gujarat Facilities
Brief: Piramal Pharma June-Quarter Consol Net Loss 693.9 Million Rupees
Brief: Piramal Pharma (Mumbai) Temporarily Suspends Operations At Ahmedabad Facilities
Brief: Piramal Pharma Receives Permanent Revocation Of Closure Order For Dahej Site
Brief: Piramal Pharma Solutions Announces Partnership With Botanix To Support Drug Substance Development
Brief: Piramal Pharma Announces Successful Closure Of Us FDA Inspection At Digwal Facility
India's Piramal Pharma eyes complex drug demand for earnings boost, chair says
Brief: Piramal Pharma Says Closure Of US FDA Inspection At Manufacturing Facility At Lexington
Brief: Piramal Pharma Says GPCB Imposed Interim Environmental Damage Compensation Of 10 Million Rupees
Brief: Piramal Pharma Introduces Tablet-In-Capsule Capabilities
Indian contract drug makers to gain global share, says HDFC Securities
Brief: Piramal Pharma Says US FDA Issued A Form-483, With Four Observations
Brief: Piramal Pharma Solutions Achieves Regulatory Compliance For Nitrosamine Impurities
Brief: Piramal Pharma Sept Quarter Consol Net Loss 992.2 Million Rupees
Brief: Piramal Pharma, Newamsterdam Pharma Invest To Enhance Oral Solid Dosage Capabilities